Bilaketaren emaitzak - David Zahrieh

Findu emaitzak
  1. 1
    Ferroportin1 is required for normal iron cycling in zebrafish

    Ferroportin1 is required for normal iron cycling in zebrafish nork Paula G. Fraenkel, David Traver, Adriana Donovan, David Zahrieh, Leonard I. Zon

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

    Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells nork Güllü Görgün, Tobias A.W. Holderried, David Zahrieh, Donna Neuberg, John G. Gribben

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays

    Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays nork George L. Mutter, David Zahrieh, Chunmei Liu, Donna Neuberg, David Finkelstein, Heather E Baker, Janet A. Warrington

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis

    X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a sub... nork Ross L. Levine, Claude Bélisle, Martha Wadleigh, David Zahrieh, Stephanie J. Lee, Pierre Chagnon, D. Gary Gilliland, Lambert Busque

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy

    Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy nork Akiko Saito, David Zahrieh, Corey Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Edwin P. Alyea, S J Lee

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93

    Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 nork Olivia Pagani, Shari Gelber, E. Simoncini, Monica Castiglione‐Gertsch, K. Price, David Zahrieh, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose Regimens

    Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose Regimens nork Akiko Saito, Corey Cutler, David Zahrieh, Robert J. Soiffer, Vincent T. Ho, Edwin P. Alyea, John Koreth, Joseph H. Antin, Stephanie J. Lee

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas

    Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas nork Palma Dileo, Jeffrey A. Morgan, David Zahrieh, Jayesh Desai, Jeanine M. Salesi, David C. Harmon, Mikayla Quigley, Kathleen Polson, George D. Demetri, Suzanne George

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Eμ- <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

    Eμ- <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction nork Güllü Görgün, Alan G. Ramsay, Tobias A.W. Holderried, David Zahrieh, Rifca Le Dieu, Fenglong Liu, John Quackenbush, Carlo M. Croce, John G. Gribben

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors

    Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors nork Chandrajit P. Raut, Matthew Posner, Jayesh Desai, Jeffrey A. Morgan, Suzanne George, David Zahrieh, Christopher D.�M. Fletcher, George D. Demetri, Monica M. Bertagnolli

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion

    Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion nork Robert J. Soiffer, Edwin P. Alyea, Ephraim P. Hochberg, Catherine J. Wu, Christine Canning, Bijal Parikh, David Zahrieh, Iain J. Webb, Joseph H. Antin, Jerome Ritz

    Argitaratua 2002
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

    Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation nork Martha Wadleigh, Paul G. Richardson, David Zahrieh, Stephanie J. Lee, Corey Cutler, Vincent T. Ho, Edwin P. Alyea, Joseph H. Antin, Richard M. Stone, Robert J. Soiffer, Daniel J. DeAngelo

    Argitaratua 2003
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

    Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial nork Stephanie J. Lee, David Zahrieh, Edward Agura, Margaret L. MacMillan, Richard T. Maziarz, Philip L. McCarthy, Vincent T. Ho, Corey Cutler, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer

    Argitaratua 2004
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy

    Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy nork Marco Colleoni, Giuseppe Viale, David Zahrieh, Luca Bottiglieri, Richard D. Gelber, Paolo Veronesi, Alessandra Balduzzi, Rosalba Torrisi, Alberto Luini, Mattia Intra, Silvia Dellapasqua, A. Cardillo, R. Ghisini, G. Peruzzotti, Aron Goldhirsch

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors

    Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors nork Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste ­Gentilini, Paolo Veronesi, Richard D. Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini, Mattia Intra, Viviana Galimberti, Giuseppe Renne, Franco Nolè, G. Peruzzotti, Aron Goldhirsch

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93

    Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-9... nork Carl‐Magnus Rudenstam, David Zahrieh, John Forbes, Diana Crivellari, Stig B. Holmberg, Piercarlo Rey, D M Dent, Ian Campbell, Jürg Bernhard, Karen N. Price, Monica Castiglione‐Gertsch, Aron Goldhirsch, Richard D. Gelber, Alan S. Coates

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials

    Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials nork Bernhard C. Pestalozzi, David Zahrieh, Elizabeth Mallon, Barry A. Gusterson, Karen N. Price, Richard D. Gelber, Stig B. Holmberg, Jurij Lindtner, Raymond Snyder, Beat Thürlimann, Elizabeth Murray, Giuseppe Viale, Monica Castiglione‐Gertsch, Alan S. Coates, Aron Goldhirsch

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

    Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia nork John G. Gribben, David Zahrieh, Katherine Stephans, L Bartlett-Pandite, Edwin P. Alyea, David C. Fisher, Arnold S. Freedman, Peter Mauch, Robert Schlossman, Lecia V. Sequist, Robert J. Soiffer, Blossom Marshall, Donna Neuberg, Jerome Ritz, Lee M. Nadler

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

    Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) nork Bernhard C. Pestalozzi, David Zahrieh, Karen N. Price, Stig B. Holmberg, Jurij Lindtner, John P. Collins, Diana Crivellari, Martin F. Fey, Elizabeth Murray, Olivia Pagani, Edda Simoncini, Monica Castiglione‐Gertsch, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

    Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia nork Eyal C. Attar, Daniel J. DeAngelo, Jeffrey G. Supko, Ferdinando D’Amato, David Zahrieh, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Steve McAfee, Kenneth B. Miller, James D. Levine, Ilene Galinsky, Elizabeth Trehu, David P. Schenkein, Donna Neuberg, Richard M. Stone, Philip C. Amrein

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: